Table 1.

Demographics and fracture characteristics of cohort

Demographics
Total patients, n	44
Genetic diagnosis	8
Diagnosis on bone biopsy	1
Sex, n (%)
Male	21 (48)
Female	23 (52)
Total patient‐years in study, n	520
Median age of cohort, years (IQR)	11.3 (6.2–17)
Age category at time of study, n (%)
0 to <3 years	3 (6.8)
3 to <6 years	7 (16)
6 to <9 years	7 (16)
9 to <12 years	6 (13.6)
12 to <15 years	6 (13.6)
15 to 18 years	15 (34)
Family history of OI, n (%)
Positive	35 (79.5)
Negative	8 (18.2)
Unknown	1 (2.2)
Extra skeletal clinical characteristics
	Yes, No, Unknown (n)
Wormian bones	9, 7, 28
Hypermobile joints	22, 6, 16
Dentinogenesis imperfecta	6, 24, 14
Gray‐blue sclerae	36, 2, 6
Hearing deficit	1, 25, 18
Fractures
Median age at first fracture, years (IQR)	1.4 (0.2–2.6)
Median age for all fractures, years (IQR)	5.0 (2.5–9.0)
Median fractures per patient (IQR)	3 (2–6)
Total fractured bones, n	197
Lower limb fractures, n (%)	98 (49.7)
Upper limb fractures, n (%)	80 (40.6)
Axial fractures, n (%)	19 (9.7)
Fracture rate (fractures/1000 patient‐years, 95% CI)	379 (310–440)
Patients with one or fewer fractures, n (%)	10 (22.7)
Patients with more than one fracture, n (%)	34 (77.3)
Patient‐years with ≥1 fracture, n (%)	130 (25)
Patient‐years with ≥2 fractures, n (%)	50 (38.4)
Patent years with same site recurrent fractures, n (%)	26 (20)
Bisphosphonates
Patients received bisphosphonates, n (%)	21 (47.8)
Median age of starting bisphosphonates, years (IQR)	6.4 (5.0–7.9)
Years when receiving bisphosphonate, n (%)
No bisphosphonate	244 (46.9)
Before bisphosphonate	131 (25.2)
During bisphosphonate	114 (21.9)
After bisphosphonate	31 (6.0)
Fracture rate (per/1000 patient‐years, 95% CI)
No bisphosphonates	230 (180–280)
Before bisphosphonates	340 (250–420)
During bisphosphonates	210 (130–290)
After bisphosphonates	190 (50–340)

Note: Results are number and percentage of total fractures or patient study years.